Maintenance therapy for platinum-sensitive recurrent ovarian cancer with a history of PARPi administration.

J Gynecol Oncol · 2026 · PMC12867658 · PMID 40878398

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Although no significant differences were observed in PFS or OS, the bevacizumab group showed a favorable trend.

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.